tickertape
← runs

TMO

THERMO FISHER SCIENTIFIC INC.eval run
10-K for period ending 2025-12-31gpt-6-luna@none · prompt v4$0.00083.5sfiling on sec.gov ↗

figures

fieldvaluestatement rowprintedSEC
Total revenue$44.6BR6 Total revenues44,556 millions$44.6B ✓
Operating income$7.7BR14 Operating income7,746 millions$7.7B ✓
Net income attributable to the company$6.7BR23 Net income attributable to Thermo Fisher Scientific Inc.6,704 millions$6.7B ✓
Diluted EPS$17.74R26 Diluted17.74$17.74 ✓
Cash and cash equivalents$9.9BR4 Cash and cash equivalents9,852 millions$9.9B ✓
Total assets$110.3BR15 Total assets110,343 millions$110.3B ✓
Total liabilities-not printed on this statement--
Total shareholders' equity attributable to the company$53.4BR37 Total Thermo Fisher Scientific Inc. shareholders’ equity53,407 millions$53.4B ✓
Net cash from operating activities$7.8BR18 Net cash provided by operating activities7,818 millions$7.8B ✓
Net cash from investing activities-$4.0BR27 Net cash used in investing activities(4,047) millions-$4.0B ✓
Net cash from financing activities$1.8BR36 Net cash provided by/(used in) financing activities1,801 millions$1.8B ✓

checks

  • assets = liabilities + equity · total assets equals total liabilities and equity
  • equity excludes minority interests · totalEquity excludes noncontrolling interests
  • net income is before preferred dividends · net income is not the after-preferred-dividends line
  • diluted EPS is for total net income · diluted EPS is for total net income
  • net income excludes minority interests · netIncome excludes noncontrolling interests
  • cash flows tie to the change in cash · not applicable: missing a section total or no net change in cash line

management's claims

No year-over-year claims about the headline figures were found in management's discussion.

trace

  1. 0locator (code)0.17s
    {
  "tables": 72,
  "exhibits": [],
  "documents": 1
}
    {
  "income": {
    "rows": 30,
    "scale": 1000000,
    "score": 51,
    "heading": "gral part of these consolidated financial statements. 33 THERMO FISHER SCIENTIFIC INC. CONSOLIDATED STATEMENTS OF INCOME",
    "tableIndex": 17,
    "runnerUpScore": 27.25
  },
  "balance": {
    "rows": 41,
    "scale": 1000000,
    "score": 53,
    "heading": "6, 2026 We have served as the Company’s auditor since 2002. 32 THERMO FISHER SCIENTIFIC INC. CONSOLIDATED BALANCE SHEETS",
    "tableIndex": 16,
    "runnerUpScore": 23.75
  },
  "cashflow": {
    "rows": 41,
    "scale": 1000000,
    "score": 53.5,
    "heading": " part of these consolidated financial statements. 35 THERMO FISHER SCIENTIFIC INC. CONSOLIDATED STATEMENTS OF CASH FLOWS",
    "tableIndex": 19,
    "runnerUpScore": 17.5
  }
}
  2. 1balance sheet agent1.70s · 1478 tokens · $0.0002
    {
  "rows": 41,
  "retryHint": null,
  "tableIndex": 16
}
    {
  "figures": [
    {
      "note": "Cash and cash equivalents is printed directly on this row.",
      "field": "cash",
      "scale": 1000000,
      "value": 9852000000,
      "printed": "9,852",
      "rowIndex": 4,
      "rowLabel": "Cash and cash equivalents",
      "priorValue": 4009000000,
      "agentPrinted": "9,852",
      "failedChecks": [],
      "priorPrinted": "4,009",
      "groundingMismatch": false
    },
    {
      "note": "This row explicitly prints total assets.",
      "field": "totalAssets",
      "scale": 1000000,
      "value": 110343000000,
      "printed": "110,343",
      "rowIndex": 15,
      "rowLabel": "Total assets",
      "priorValue": 97321000000,
      "agentPrinted": "110,343",
      "failedChecks": [],
      "priorPrinted": "97,321",
      "groundingMismatch": false
    },
    {
      "note": "The statement does not print a standalone total liabilities line.",
      "field": "totalLiabilities",
      "scale": 1000000,
      "value": null,
      "printed": null,
      "rowIndex": null,
      "rowLabel": null,
      "priorValue": null,
      "agentPrinted": null,
      "failedChecks": [],
      "priorPrinted": null,
      "groundingMismatch": false
    },
    {
      "note": "This is the company shareholders’ equity total, excluding noncontrolling interests.",
      "field": "totalEquity",
      "scale": 1000000,
      "value": 53407000000,
      "printed": "53,407",
      "rowIndex": 37,
      "rowLabel": "Total Thermo Fisher Scientific Inc. shareholders’ equity",
      "priorValue": 49584000000,
      "agentPrinted": "53,407",
      "failedChecks": [],
      "priorPrinted": "49,584",
      "groundingMismatch": false
    }
  ],
  "statement": "balance",
  "tableIndex": 16,
  "priorColumn": 1,
  "currentColumn": 0
}
  3. 2cash flow agent1.75s · 1509 tokens · $0.0002
    {
  "rows": 41,
  "retryHint": null,
  "tableIndex": 19
}
    {
  "figures": [
    {
      "note": "This is the operating activities section total, including changes in working capital.",
      "field": "operatingCashFlow",
      "scale": 1000000,
      "value": 7818000000,
      "printed": "7,818",
      "rowIndex": 18,
      "rowLabel": "Net cash provided by operating activities",
      "priorValue": 8667000000,
      "agentPrinted": "7,818",
      "failedChecks": [],
      "priorPrinted": "8,667",
      "groundingMismatch": false
    },
    {
      "note": "This is the net cash total for investing activities.",
      "field": "investingCashFlow",
      "scale": 1000000,
      "value": -4047000000,
      "printed": "(4,047)",
      "rowIndex": 27,
      "rowLabel": "Net cash used in investing activities",
      "priorValue": -5841000000,
      "agentPrinted": "(4,047)",
      "failedChecks": [],
      "priorPrinted": "(5,841)",
      "groundingMismatch": false
    },
    {
      "note": "This is the net cash total for financing activities.",
      "field": "financingCashFlow",
      "scale": 1000000,
      "value": 1801000000,
      "printed": "1,801",
      "rowIndex": 36,
      "rowLabel": "Net cash provided by/(used in) financing activities",
      "priorValue": -6792000000,
      "agentPrinted": "1,801",
      "failedChecks": [],
      "priorPrinted": "(6,792)",
      "groundingMismatch": false
    }
  ],
  "statement": "cashflow",
  "tableIndex": 19,
  "priorColumn": 1,
  "currentColumn": 0
}
  4. 3income statement agent1.91s · 1567 tokens · $0.0002
    {
  "rows": 30,
  "retryHint": null,
  "tableIndex": 17
}
    {
  "figures": [
    {
      "note": "Total revenues is the company-wide revenue line.",
      "field": "revenue",
      "scale": 1000000,
      "value": 44556000000,
      "printed": "44,556",
      "rowIndex": 6,
      "rowLabel": "Total revenues",
      "priorValue": 42879000000,
      "agentPrinted": "44,556",
      "failedChecks": [],
      "priorPrinted": "42,879",
      "groundingMismatch": false
    },
    {
      "note": "This row explicitly reports operating income.",
      "field": "operatingIncome",
      "scale": 1000000,
      "value": 7746000000,
      "printed": "7,746",
      "rowIndex": 14,
      "rowLabel": "Operating income",
      "priorValue": 7337000000,
      "agentPrinted": "7,746",
      "failedChecks": [],
      "priorPrinted": "7,337",
      "groundingMismatch": false
    },
    {
      "note": "This is net income attributable to Thermo Fisher Scientific Inc., excluding noncontrolling interests.",
      "field": "netIncome",
      "scale": 1000000,
      "value": 6704000000,
      "printed": "6,704",
      "rowIndex": 23,
      "rowLabel": "Net income attributable to Thermo Fisher Scientific Inc.",
      "priorValue": 6335000000,
      "agentPrinted": "6,704",
      "failedChecks": [],
      "priorPrinted": "6,335",
      "groundingMismatch": false
    },
    {
      "note": "This row reports diluted earnings per share attributable to Thermo Fisher Scientific Inc.",
      "field": "epsDiluted",
      "scale": 1,
      "value": 17.74,
      "printed": "17.74",
      "rowIndex": 26,
      "rowLabel": "Diluted",
      "priorValue": 16.53,
      "agentPrinted": "17.74",
      "failedChecks": [],
      "priorPrinted": "16.53",
      "groundingMismatch": false
    }
  ],
  "statement": "income",
  "tableIndex": 17,
  "priorColumn": 1,
  "currentColumn": 0
}
  5. 4reconciler (code)0.00s
    null
    [
  {
    "name": "balance_identity",
    "detail": "total assets equals total liabilities and equity",
    "fields": [
      "totalAssets"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "totalEquity_attribution",
    "detail": "totalEquity excludes noncontrolling interests",
    "fields": [
      "totalEquity"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "netIncome_before_preferred",
    "detail": "net income is not the after-preferred-dividends line",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "epsDiluted_total",
    "detail": "diluted EPS is for total net income",
    "fields": [
      "epsDiluted"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "netIncome_attribution",
    "detail": "netIncome excludes noncontrolling interests",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "cash_flow_tie",
    "detail": "missing a section total or no net change in cash line",
    "fields": [
      "operatingCashFlow",
      "investingCashFlow",
      "financingCashFlow"
    ],
    "passed": true,
    "skipped": true,
    "statement": "cashflow"
  }
]
  6. 5MD&A claims agent1.10s · 1655 tokens · $0.0002
    null
    []

Income statement

table #17 · current period is figure column 1
0Year Ended
1December 31,December 31,December 31,
2(In millions except per share amounts)202520242023
3Revenues
4Product revenues25,96525,03425,243
5Service revenues18,59217,84517,614
6Total revenues← Total revenue44,55642,87942,857
7Costs and operating expenses:
8Cost of product revenues13,40512,52313,168
9Cost of service revenues12,91312,65412,589
10Selling, general and administrative expenses8,7328,5958,445
11Research and development expenses1,3971,3901,337
12Restructuring and other costs362379459
13Total costs and operating expenses36,81035,54235,998
14Operating income← Operating income7,7467,3376,859
15Interest income9931,078879
16Interest expense(1,419)(1,390)(1,375)
17Other income/(expense)(12)12(65)
18Income before income taxes7,3087,0376,298
19Benefit from/(provision for) income taxes(547)(657)(284)
20Equity in earnings/(losses) of unconsolidated entities(41)(42)(59)
21Net income6,7216,3385,955
22Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest173(40)
23Net income attributable to Thermo Fisher Scientific Inc.← Net income attributable to the company6,7046,3355,995
24Earnings per share attributable to Thermo Fisher Scientific Inc.
25Basic17.7716.5815.52
26Diluted← Diluted EPS17.7416.5315.45
27Weighted average shares
28Basic377382386
29Diluted378383388

Balance sheet

table #16 · current period is figure column 1
0December 31,December 31,
1(In millions except share and per share amounts)20252024
2Assets
3Current assets:
4Cash and cash equivalents← Cash and cash equivalents9,8524,009
5Short-term investments2531,561
6Accounts receivable, less allowances of $147 and $1738,9008,191
7Inventories5,4254,978
8Contract assets, net1,6661,435
9Other current assets2,6121,964
10Total current assets28,70722,137
11Property, plant and equipment, net10,5659,306
12Acquisition-related intangible assets, net15,83815,533
13Other assets5,8714,492
14Goodwill49,36245,853
15Total assets← Total assets110,34397,321
16Liabilities, redeemable noncontrolling interest and equity
17Current liabilities:
18Short-term obligations and current maturities of long-term obligations3,5332,214
19Accounts payable3,6223,079
20Accrued payroll and employee benefits1,9951,988
21Contract liabilities2,7102,852
22Other accrued expenses3,3293,199
23Total current liabilities15,18913,332
24Deferred income taxes1,4931,268
25Other long-term liabilities4,2733,989
26Long-term obligations35,85229,061
27Commitments and contingencies (Note 5)
28Redeemable noncontrolling interest122120
29Equity:
30Thermo Fisher Scientific Inc. shareholders’ equity:
31Preferred stock, $100 par value, 50,000 shares authorized; none issued--
32Common stock, $1 par value, 1,200,000,000 shares authorized; 445,160,301 and 443,841,240 shares issued445444
33Capital in excess of par value18,56317,962
34Retained earnings59,15653,102
35Treasury stock at cost, 68,938,831 and 63,066,906 shares(22,309)(19,226)
36Accumulated other comprehensive income/(loss)(2,448)(2,697)
37Total Thermo Fisher Scientific Inc. shareholders’ equity← Total shareholders' equity attributable to the company53,40749,584
38Noncontrolling interests7(33)
39Total equity53,41549,551
40Total liabilities, redeemable noncontrolling interest and equity110,34397,321

Cash flow statement

table #19 · current period is figure column 1
0Year Ended
1December 31,December 31,December 31,
2(In millions)202520242023
3Operating activities
4Net income6,7216,3385,955
5Adjustments to reconcile net income to net cash provided by operating activities:
6Depreciation of property, plant and equipment1,0501,1561,068
7Amortization of acquisition-related intangible assets1,7301,9522,338
8Change in deferred income taxes(639)(1,209)(1,300)
9Stock-based compensation310301278
10Other net non-cash expenses455508604
11Changes in assets and liabilities, excluding the effects of acquisitions:
12Accounts receivable(426)(171)(43)
13Inventories(74)(27)598
14Contract assets/liabilities(375)(162)252
15Accounts payable421212(500)
16Contributions to retirement plans(42)(45)(42)
17Other(1,312)(186)(802)
18Net cash provided by operating activities← Net cash from operating activities7,8188,6678,406
19Investing activities
20Purchases of property, plant and equipment(1,525)(1,400)(1,479)
21Proceeds from sale of property, plant and equipment445787
22Proceeds from cross-currency interest rate swap interest settlements26825270
23Acquisitions, net of cash acquired(4,037)(3,132)(3,660)
24Purchases of investments(383)(3,396)(208)
25Proceeds from sales and maturities of investments1,5651,77015
26Other investing activities, net21833
27Net cash used in investing activities← Net cash from investing activities(4,047)(5,841)(5,142)
28Financing activities
29Net proceeds from issuance of debt7,7591,2045,942
30Repayment of debt(2,412)(3,607)(5,782)
31Proceeds from issuance of commercial paper1,095-1,620
32Repayments of commercial paper(1,095)-(1,935)
33Purchases of company common stock(3,000)(4,000)(3,000)
34Dividends paid(636)(583)(523)
35Other financing activities, net9019556
36Net cash provided by/(used in) financing activities← Net cash from financing activities1,801(6,792)(3,622)
37Exchange rate effect on cash267(91)(82)
38Increase/(decrease) in cash, cash equivalents and restricted cash5,839(4,057)(440)
39Cash, cash equivalents and restricted cash at beginning of year4,0408,0978,537
40Cash, cash equivalents and restricted cash at end of year9,8794,0408,097